Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) EBITDA (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed EBITDA for 6 consecutive years, with -$26.5 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 26.5% to -$26.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$148.3 million through Dec 2025, changed 0.41% year-over-year, with the annual reading at -$148.3 million for FY2025, 0.41% changed from the prior year.
  • EBITDA for Q4 2025 was -$26.5 million at Caribou Biosciences, up from -$27.5 million in the prior quarter.
  • The five-year high for EBITDA was -$9.8 million in Q3 2023, with the low at -$54.2 million in Q2 2025.
  • Average EBITDA over 5 years is -$28.3 million, with a median of -$27.2 million recorded in 2022.
  • The sharpest move saw EBITDA plummeted 534.63% in 2021, then soared 63.67% in 2023.
  • Over 5 years, EBITDA stood at -$18.6 million in 2021, then plummeted by 42.22% to -$26.5 million in 2022, then fell by 26.53% to -$33.5 million in 2023, then decreased by 7.55% to -$36.0 million in 2024, then grew by 26.5% to -$26.5 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$26.5 million, -$27.5 million, and -$54.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.